BRCA1 and cancer: Due to the challenges of detecting reversion mutation and the limited usage of PARP inhibitors in clinical trials, data gathered from massive-scale research to assess the prevalence of BRCA1/2 gene reactivation in cancer patients having PARP inhibitor-resistant tumors are missing even now.